After a prolonged slump, the pharmaceutical sector has regained market traction and emerged as a core potential sector for A-shares in the fourth quarter. Latest public fund performance data shows that pharmaceutical-themed funds have swept the top 15 rankings of active equity funds over the past three months, completely reversing the market pattern where tech sectors dominated and pharmaceutical stocks lagged for the first half of the year.

The current rebound of the pharmaceutical industry is not a short-term market speculation, but a comprehensive resonance of performance recovery, valuation restoration and policy dividends. After long-term adjustments, the overall valuation of the pharmaceutical sector has fallen to a five-year low with sufficient bubble clearance, offering high cost performance for asset allocation. On the fundamental side, multiple pharmaceutical enterprises have launched innovative drug pipelines and witnessed growing export orders for medical devices, marking a turning point in corporate profitability and ending the prolonged performance downturn.

Continuous positive policy signals have boosted the industry, including accelerated approval for medical innovations and optimized national medical insurance negotiation mechanisms, removing major development barriers. Compared with overvalued hard tech sectors such as AI and semiconductors, the pharmaceutical sector boasts superior risk-return ratio, becoming a core allocation choice for public funds’ position adjustments. Industry insiders predict that with the completion of institutional year-end position adjustments and sustained performance growth, the pharmaceutical recovery rally will continue. Segmented tracks including innovative drugs, high-end medical devices and pharmaceutical consumption are expected to lead gains and become a new growth pillar in the capital market.